Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2012, Article ID 672923, 4 pages
http://dx.doi.org/10.1155/2012/672923
Case Report

Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem Cell Transplantations for Acute Lymphoblastic Leukemia

1Department of Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Hoppe-Seyler-Strß 1, 72076 Tübingen, Germany
2Department of Pediatric Diagnostic Radiology, Olga-Hospital Stuttgart, Bismarckstraß 8, 70176 Stuttgart, Germany
3Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Martinistraß 52, 20246 Hamburg, Germany

Received 16 May 2012; Accepted 7 August 2012

Academic Editors: F. Keller and S. Le Gouill

Copyright © 2012 Michaela Döring et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Kontoyiannis, R. Hachem, R. E. Lewis et al., “Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies,” Cancer, vol. 98, no. 2, pp. 292–299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. D. W. Denning, “Therapeutic outcome in invasive aspergillosis,” Clinical Infectious Diseases, vol. 23, no. 3, pp. 608–615, 1996. View at Google Scholar · View at Scopus
  3. D. Caillot, A. Thiébaut, R. Herbrecht et al., “Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (combistrat trial),” Cancer, vol. 110, no. 12, pp. 2740–2746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-P. Latgé, “Aspergillus fumigatus and aspergillosis,” Clinical Microbiology Reviews, vol. 12, no. 2, pp. 310–350, 1999. View at Google Scholar · View at Scopus
  5. T. J. Walsh, J. W. Hiemenz, N. L. Seibel et al., “Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases,” Clinical Infectious Diseases, vol. 26, no. 6, pp. 1383–1396, 1998. View at Google Scholar · View at Scopus
  6. L. B. Johnson and C. A. Kauffman, “Voriconazole: a new triazole antifungal agent,” Clinical Infectious Diseases, vol. 36, no. 5, pp. 630–637, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Herbrecht, D. W. Denning, T. F. Patterson et al., “Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis,” New England Journal of Medicine, vol. 347, no. 6, pp. 408–415, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Maertens, I. Raad, G. Petrikkos et al., “Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy,” Clinical Infectious Diseases, vol. 39, no. 11, pp. 1563–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Walsh, H. Teppler, G. R. Donowitz et al., “Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia,” New England Journal of Medicine, vol. 351, no. 14, pp. 1391–1474, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Herbrecht, J. Maertens, L. Baila et al., “Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer Study,” Bone Marrow Transplantation, vol. 45, no. 7, pp. 1227–1233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. S. Chou, R. E. Lewis, C. Ippoliti, R. E. Champlin, and D. P. Kontoyiannis, “Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients,” Pharmacotherapy, vol. 27, no. 12 I, pp. 1644–1650, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Nivoix, A. Zamfir, P. Lutun et al., “Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections,” Journal of Infection, vol. 52, no. 1, pp. 67–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. A. Marr, M. Boeckh, R. A. Carter, W. K. Hyung, and L. Corey, “Combination antifungal therapy for invasive aspergillosis,” Clinical Infectious Diseases, vol. 39, no. 6, pp. 797–802, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Pancham, C. Hemmaway, H. New et al., “Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation,” Pediatric Transplantation, vol. 9, no. 2, pp. 254–257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Maertens, A. Glasmacher, R. Herbrecht et al., “Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis,” Cancer, vol. 107, no. 12, pp. 2888–2897, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Woods, M. H. Miceli, M. L. Grazziutti, W. Zhao, B. Barlogie, and E. Anaissie, “Serum aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer,” Cancer, vol. 110, no. 4, pp. 830–834, 2007. View at Publisher · View at Google Scholar · View at Scopus